Search Results for: covid-19
Articles
Immunic, Inc. Reports Positive Top-line Data From Phase 2 EMPhASIS Trial
Immunic, Inc. recently announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company’s selective...Corbus Pharmaceuticals Completes Enrollment in Phase 3 Study
Corbus Pharmaceuticals Holdings, Inc. recently announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy...Don’t Miss RNA Medicine in a Pandemic Symposium on July 23!
Join us as we are hosting an RNA Symposium bringing together leading experts in RNA medicine, delivery, technology development, and solutions for manufacturing to present and discuss…
Timber Pharmaceuticals Announces All CONTROL Study Sites Open & Enrolling Patients With Moderate-to-Severe Congenital Ichthyosis
Timber Pharmaceuticals, Inc. recently announced that all 11 sites across the US and Australia participating in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) are now….
2020 Respiratory Drug Development eBook – Inhaled Medications for Treating Unconventional Respiratory Diseases
This second annual Drug Development & Delivery Respiratory eBook focuses on a few companies that are taking inhalation devices to a new level in drug delivery.
Ajinomoto Bio-Pharma Services Introduces AJILITY Fast-Track Platform for Drug Product Manufacturing
Ajinomoto Bio-Pharma Services recently announce the launch of AJILITY, a flexible and agile drug product manufacturing platform, designed to advance….
Bormioli Pharma Invests in Type I Glass Vial Production for Injectable Medicines & Vaccines
The global, Covid-19 pandemic emergency has not weakened Bormioli Pharma's determination to keep on investing and supporting its customers. After...Mateon & GMP Completed Research & Service Agreement
Mateon Therapeutics, Inc. recently announced that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement entered on….
Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Blindness
Bionic Sight, LLC recently announced it has dosed the first patient in the company’s Phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with….
Arch Biopartners Announces FDA Acknowledgement of its IND Application
Arch Biopartners Inc. recently announced the US FDA has received and acknowledged the Investigational New Drug (IND) Application for its...
